Advertisement

Topics

Cleveland BioLabs to Report Second Quarter 2015 Financial Results on August 3

20:00 EDT 20 Jul 2015 | Marketwired

BUFFALO, NY -- (Marketwired) -- 07/21/15 -- Cleveland BioLabs, Inc.
(NASDAQ: CBLI) today announced that on August 3, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015, and will host a conference call at 10:00 a.m. ET.

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs website at www.cbiolabs.com.

A replay of the call will be available starting on August 3, 2015, at 1:00 p.m. ET through August 17, 2015, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13613931. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs website at www.cbiolabs.com.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

Contact: Rachel Levine Vice President Investor Relations Cleveland BioLabs, Inc. T: (917) 375-2935 Email: NEXT ARTICLE

More From BioPortfolio on "Cleveland BioLabs to Report Second Quarter 2015 Financial Results on August 3 "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...